Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates
Open Access
- 20 January 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 759
Abstract
Despite recent advances in targeted drug delivery, approved Antibody-Drug-Conjugates (ADCs) are still limited by the delivery of a restricted set of payloads with limited modes of action (MOA). Versatile linkers, applicable to functional groups prevalent across diverse pharmacophores are needed to expand this space. We present phosphoramidate-based self-immolative linker-units that facilitate stable attachment in serum and traceless drug release in the target cell of aliphatic and aromatic alcohols. Studies with camptothecins show that stability and release are tunable and that various intracellular trigger events can be exploited to ensure traceless drug delivery. Superior stability, in vivo efficacy, and pharmacokinetics (PK) compared to approved camptothecin ADCs are demonstrated. Moreover, we report targeted delivery of 10 different hydroxy-containing cytotoxins with different intracellular MOAs. In vivo studies with gemcitabine show excellent PK and efficacy, unlocking gemcitabine’s full potential and illustrating the ability of the phosphoramidate-based linker system to expand the payload space for ADCs.Keywords
All Related Versions
This publication has 77 references indexed in Scilit:
- 42P Safety, tolerability, pharmacokinetics, and antitumor activity of FDA022-BB05 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase I/Ib studyAnnals of Oncology, 2024
- Thio-ProTide strategy: A novel H2S donor–drug conjugate (DDC) alleviates hepatic injury via innate lysosomal targetingActa Pharmaceutica Sinica B, 2024
- Unlocking Amides: A General Method for the Self‐Immolative Release of Amide‐Containing MoleculesAngewandte Chemie International Edition, 2024
- Antibody–drug conjugates: Recent advances in payloadsActa Pharmaceutica Sinica B, 2023
- The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agentCancer Chemotherapy and Pharmacology, 2023
- Sacituzumab Govitecan: First ApprovalDrugs, 2020
- Cysteine‐Selective Phosphonamidate Electrophiles for Modular Protein BioconjugationsAngewandte Chemie International Edition, 2019
- The Methylene Alkoxy Carbamate Self‐Immolative Unit: Utilization for the Targeted Delivery of Alcohol‐Containing Payloads with Antibody–Drug ConjugatesAngewandte Chemie International Edition, 2016
- Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveCancer Chemotherapy and Pharmacology, 2016
- Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker systemBioorganic & Medicinal Chemistry Letters, 2009